Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.46 |
| ▸ | HRH1 | P35367 | 4/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22281941 | 0.94 | CYP2D6 (0.48) | HRH3HRH1HRH2ACHESPHK1 | |
| SCHEMBL10059171 | 0.89 | HRH3 (0.48) | HRH3HRH1HRH2ACHECYP2D6 | |
| SCHEMBL10059156 | 0.89 | HRH3 (0.48) | HRH3HRH1HRH2ACHECYP2D6 | |
| SCHEMBL8897615 | 0.87 | SPHK1 (0.46) | HRH3HRH1HRH2ACHESPHK1 | |
| SCHEMBL29322718 | 0.83 | MAPK1 (0.40) | HRH3CYP2D6CYP2C19ALDH1A1RAB9A | |
| SCHEMBL11569854 | 0.83 | — | — | |
| SCHEMBL21738353 | 0.82 | HRH3 (0.45) | HRH3HRH1CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL21000316 | 0.82 | GLB1 (0.42) | HRH3HRH1HRH2CYP2D6CYP2C19 | |
| SCHEMBL12717293 | 0.82 | HRH3 (0.47) | HRH3HRH1HRH2ACHESPHK1 | |
| SCHEMBL21933658 | 0.82 | SIGMAR1 (0.53) | HRH3HRH1HRH2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2021195599-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-11059834-B2 | Macrocyclic immunomodulators | CHEMOCENTRYX, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| WO-2020154447-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20200055869-A1 | MACROCYCLIC IMMUNOMODULATORS | CHEMOCENTRYX, INC. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059834-B2 | Macrocyclic immunomodulators | IL2, IL2RA, C3AR1 | HRH3 162/4885HRH1 234/4885HRH2 158/4885 |
| US-20200055869-A1 | MACROCYCLIC IMMUNOMODULATORS | IL2, IL2RA, C3AR1 | HRH3 162/4885HRH1 234/4885HRH2 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.